PDF《2018》

the Group and we shall refer to the Company and its Subsidiaries;

Subsidiary(ies) shall refer to the subsidiaries of the Company;

the Board shall refer to the board of directors of the Company and PRC shall refer to the People'

s Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited

4 Environmental, Social and Governance Report 1.4 Reliability Assurance The Board and senior management of the Group have reviewed and approved this report on

13 June

2019 and guarantee that it does not contain any false information, misleading statement or material omission. 1.5 Access to This Report This report is prepared both in Chinese and English. In case of inconsistency, the Chinese version shall prevail over the English version. Electronic version of this report is available for downloading from the website of the Company at http:// www.interlong.com. For enquiry or suggestion regarding this report, please feel free to contact us at: Contact: Ms. Mu Ling Xia and Ms. Xie Tian Tian Address: Suite 2103, 21st floor, Neptunus Yinhe Technology Mansion,

1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the PRC Tel: (86)

755 26411869, (86)

755 86573914 Fax: (86)

755 86391610 Postal Code:

518000 Environmental, Social and Governance Report

2018 5 Environmental, Social and Governance Report

2 Message from Chairman I am pleased to present the ESG Report of the Group as of

31 December 2018.

2018 was a year of adjustment and building up of strength for Neptunus Interlong. As the supply-side reform of the State continues, its overall economy maintained a development trend of stable performance and at the same time achieved progress. Following the release of the 4+7 centralised procurement policy and the extensive promotion and in-depth implementation of two invoice system (两票制) and one invoice system (一票制) in the PRC, China'

s pharmaceutical industry will face a new market landscape. In adapting to the impact of the implementation of two invoice system and one invoice system , the Group has made proactive adjustment to its existing business model. The Group has actively responded to opportunities and challenges brought by national policies and industrial trend and closely monitored such policies and trend. While carefully optimizing its operating strategies, the Group adheres to the mission of serving the health of the public , actively shoulders corporate social responsibility, strengthens communication and cooperation with stakeholders and pursues sustainable development of the economy, society and environment with joint effort. The Group made various progresses in promoting sustainable development in the year. During the year, we continued to improve ESG governance structure and established an ESG Leading Team of the Group and ESG Working Teams in the Subsidiaries to deepen the effect of ESG management on the sustainable development of the enterprise. At the same time, we achieved progress in the certification of pharmaceutical production qualification and relevant Subsidiaries have re-obtained the Pharmaceutical GMP Certificates. Furthermore, our research and development capabilities received new recognition. A Subsidiary of the Group was selected as one of the

2018 Fujian Province Little Giant Leading Enterprises in Science and Technology (福建 省2018年度科技小巨人领军企业) and was granted a special fund as an award of additional tax deduction on research and development expenses. The applications for two invention patents of the said Subsidiary were also accepted. Looking into 2019, the Group will align with policy updates and macro-trends, proactively respond to opportunities and challenges arising from adjustment of the industry. While maintaining the good and steady momentum of business growth, the Group will put more emphasis on the performance of corporate social responsibility and continue to make contribution to the sustainable development of the pharmaceutical and healthcare industry of the PRC and the health of mankind. Zhang Feng Chairman of the Board